Emoled s.r.l. partners with Kerr Biotech

Emoled, a medical device manufacturer based in Florence Italy, and pioneers of the EmoLED blue-light device have formed a local partnership with Kerr Biotech (formerly Balter Healthcare) to market and distribute the innovative device in Australia/New Zealand.

Kerr Biotech Managing Director Mr Matthew Kerr said in a statement that "it's great to be pushing the boundaries of clinical competency with phototherapies utilizing blue light, it's been some time since technology with so much potential has been offered to wound specialists".

For those new to EmoLED, the class IIa device is supported by a growing number of clinical publications that its use significantly reduces the burden of chronic wounds via photo-biomodulation (PBM) - a process by which light interacts with light-sensitive cell components such as chromophores.

A world-first multi-center, prospective controlled clinical study titled BLUR (Blue Light for Ulcer Reduction) reported significant reductions in wound-associated pain, reductions in the signs of inflammation, and a greater reduction in wound surface area vs standard care alone. These results were obtained in a real-world population with an average wound age exceeding 5 years! More details on this study will follow shortly as Balter Healthcare begins the introductory phase of EmoLED devices across Australias busy wound care centers.

Excitingly there is a multi-center, randomized controlled study titled LUCE (Leg Ulcers Standard of Care Enhancement) already enrolling to replicate the outcomes of the BLUR study to further promote evidence-based biophotomodulation therapy with EmoLEDs blue light technology.

For more details on the EmoLED device head to www.emoled.com